Biontech Se Sponsored Adr ((BNTX)), Biontech SE (($CC:BNTX.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioNTech SE is currently sponsoring a clinical study titled ‘A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer.’ The study aims to assess the efficacy and safety of a combination therapy involving BNT324 and BNT327 in patients with advanced lung cancer, focusing on both small cell and non-small cell lung cancer types.
The intervention being tested involves two biological agents: BNT324, a B7-H3 antibody-drug conjugate, and BNT327, a bispecific antibody targeting PD-L1 and VEGF. These agents are administered via intravenous infusion and are designed to enhance the treatment of advanced lung cancer.
The study follows an interventional design with a randomized allocation and parallel intervention model. It is an open-label study with no masking, primarily aimed at treatment. The study is divided into two parts, focusing on dose escalation and efficacy evaluation.
Key dates for the study include an actual start date of May 2, 2025, with the latest update submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.
This study could significantly impact BioNTech’s stock performance and investor sentiment, as successful results may enhance the company’s position in the oncology market. The involvement of collaborators like DualityBio Inc. and Biotheus Inc. also highlights the competitive landscape in cancer therapeutics.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.